About: LY-320,135

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s. LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses.

Property Value
dbo:abstract
  • LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s. LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses. (en)
dbo:casNumber
  • 176977-56-3
dbo:chEMBL
  • 411481
dbo:fdaUniiCode
  • CJY03984CT
dbo:pubchem
  • 5311257
dbo:thumbnail
dbo:wikiPageID
  • 17305129 (xsd:integer)
dbo:wikiPageLength
  • 3275 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1082424528 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 24 (xsd:integer)
dbp:casNumber
  • 176977 (xsd:integer)
dbp:chembl
  • 411481 (xsd:integer)
dbp:chemspiderid
  • 4470772 (xsd:integer)
dbp:h
  • 17 (xsd:integer)
dbp:iupacName
  • 4 (xsd:integer)
dbp:iupharLigand
  • 742 (xsd:integer)
dbp:molecularWeight
  • 383.395000 (xsd:double)
dbp:n
  • 1 (xsd:integer)
dbp:o
  • 4 (xsd:integer)
dbp:pubchem
  • 5311257 (xsd:integer)
dbp:smiles
  • c3ccccc3-c2oc1ccccc1c2Cc4ccccc4 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • RYNSGDFWBJWWSZ-UHFFFAOYSA-N (en)
dbp:unii
  • CJY03984CT (en)
dbp:verifiedrevid
  • 424674882 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s. LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses. (en)
rdfs:label
  • LY-320,135 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License